Physician

Mark E Staniforth, MD

According to 2025 Medicare claims, Mark Staniforth, MD (NPI: 1619978707) practices nephrology in the Muskegon-Norton Shores, MI market, with the plurality of this provider's patient population coming from Muskegon, MI. This provider's primary affiliated billing organization is WEST MICHIGAN NEPHROLOGY PLLC (NPI: 1235143090; TIN: 382690980) and primary practice location at 49444-1881. Staniforth is affiliated with the Trinity Health Integrated Care (ACO ID: A3454) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Staniforth's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 404 traditional Medicare patients, billed 864 HCPCS/CPT codes, and received $91,009 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,239 prescription claims across 338 beneficiaries totaling $215,523 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 67 claims. Open Payments data shows 1 records totaling $27. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $191,859 to $91,009. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $482,949 to $215,523. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,567 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$119K$238K2015 Medicare payment: $191,859 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $210,962 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $237,943 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $200,416 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $217,964 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $152,294 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $171,515 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $138,550 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $106,291 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $91,009 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20156512,051$191,859
20167892,386$210,962
20177462,567$237,943
20186222,129$200,416
20197102,149$217,964
20206341,567$152,294
20215001,343$171,515
20224991,266$138,550
20234471,081$106,291
2024404864$91,009

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$257K$513K2015 Drug cost: $482,949 (USD; Tot_Drug_Cst)2016 Drug cost: $513,093 (USD; Tot_Drug_Cst)2017 Drug cost: $414,404 (USD; Tot_Drug_Cst)2018 Drug cost: $163,465 (USD; Tot_Drug_Cst)2019 Drug cost: $204,965 (USD; Tot_Drug_Cst)2020 Drug cost: $226,191 (USD; Tot_Drug_Cst)2021 Drug cost: $119,561 (USD; Tot_Drug_Cst)2022 Drug cost: $375,781 (USD; Tot_Drug_Cst)2023 Drug cost: $261,455 (USD; Tot_Drug_Cst)2024 Drug cost: $215,523 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20154183,004$482,949
20164132,552$513,093
20174232,358$414,404
20183941,989$163,465
20193141,493$204,965
20203341,289$226,191
20213371,170$119,561
20223601,320$375,781
20232971,119$261,455
20243381,239$215,523

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$18K$37K2015 Medicare payment: $36,482 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $36,822 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $26,403 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $32,273 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $12,852 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $6,252 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $162 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $533 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $1,206 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
201576396$36,482
201694503$36,822
201779410$26,403
201879495$32,273
201965295$12,852
202011142$6,252
2021N/R12$162
2022N/RN/RN/R
2023N/R37$533
2024N/R67$1,206

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
90960Dialysis services, 4 or more physician visits per month (20 years or older)121204$231
99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes4654$89
99232Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes68235$54
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more135155$54
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more6771$48

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FarxigaDapagliflozin Propanediol853,580$65,306
KerendiaFinerenone171,350$25,051
JardianceEmpagliflozin21840$15,604
LokelmaSodium Zirconium Cyclosilicate21622$9,585
SpsSodium Polystyrene Sulfon/Sorb29776$8,764

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J7507Tacrolimus, immediate release, oral, 1 mgNN/R13$394
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodNN/R25$288
J7517Mycophenolate mofetil, oral, 250 mgNN/R15$279
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R14$245

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.1$27Travere Therapeutics, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark E. Staniforth, MD?

Tedicare shows public-source Medicare data for Mark E. Staniforth, MD (NPI 1619978707), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark E. Staniforth, MD have ACO affiliation data?

Mark E. Staniforth, MD is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Mark E. Staniforth, MD?

Mark E. Staniforth, MD is linked to WEST MICHIGAN NEPHROLOGY PLLC (billing NPI 1235143090) in the available physician profile data.

Does Mark E. Staniforth, MD have Open Payments data?

Mark E. Staniforth, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.